{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:28:13Z","timestamp":1790872093323,"version":"4.1.0"},"reference-count":172,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Huntington's disease is a hereditary neurodegenerative disorder marked by severe neurodegeneration\nin the striatum and cortex. Brain-derived neurotrophic factor (BDNF) is a member of the\nneurotrophin family of growth factors. It plays a crucial role in maintaining the survival and proper\nfunction of striatal neurons. Depletion of BDNF has been linked to impairment and death of striatal\nneurons, leading to the manifestation of motor, cognitive, and behavioral dysfunctions characteristic of\nHuntington's disease. This review highlights the current update on the neurobiology of BDNF in the\npathogenesis of Huntington's disease. The molecular evidence and the affected signaling pathways are\nalso discussed. In addition, the impact of experimental manipulation of BDNF levels and its pharmaceutical\npotential for Huntington's disease treatment are explicitly reviewed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x22666240530105516","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T09:26:37Z","timestamp":1736241997000},"page":"384-403","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Brain-Derived Neurotrophic Factor (BDNF) in Huntington\u2019s Disease: Neurobiology and Therapeutic Potential"],"prefix":"10.2174","volume":"23","author":[{"given":"Khairunnuur Fairuz","family":"Azman","sequence":"first","affiliation":[{"name":"Department of Physiology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kota Bharu,\nKelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahimah","family":"Zakaria","sequence":"additional","affiliation":[{"name":"Department of Physiology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kota Bharu,\nKelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"c3109","DOI":"10.1136\/bmj.c3109","volume":"340","author":"Novak MJU","year":"2010","unstructured":"Novak MJU; Tabrizi SJ; Huntington\u2019s disease. BMJ  2010,340(jun30 4),c3109","journal-title":"BMJ"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12974-022-02419-9","volume":"19","author":"Chen K.P.","year":"2022","unstructured":"Chen K.P.; Hua K.F.; Tsai F.T.; A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington\u2019s disease. J Neuroinflammation  2022,19(1),56","journal-title":"J Neuroinflammation"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/nmt-2016-0008","volume":"6","author":"Baig S.S.","year":"2016","unstructured":"Baig S.S.; Strong M.; Quarrell O.W.J.; The global prevalence of Huntington\u2019s disease: A systematic review and discussion. Neurodegener Dis Manag  2016,6(4),331-343","journal-title":"Neurodegener Dis Manag"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"Rawlins M.D.","year":"2016","unstructured":"Rawlins M.D.; Wexler N.S.; Wexler A.R.; The prevalence of Huntington\u2019s disease. Neuroepidemiology  2016,46(2),144-153","journal-title":"Neuroepidemiology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e4f8606b742ef3","DOI":"10.1371\/4f8606b742ef3","volume":"4","author":"Quarrell O","year":"2012","unstructured":"Quarrell O; O\u2019Donovan KL; Bandmann O; Strong M; The prevalence of juvenile Huntington\u2019s disease: A review of the literature and meta-analysis. PLoS Curr  2012,4,e4f8606b742ef3","journal-title":"PLoS Curr"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28855","volume":"37","author":"Ferreira J.J.","year":"2022","unstructured":"Ferreira J.J.; Rodrigues F.B.; Duarte G.S.; An MDS evidence\u2010based review on treatments for Huntington\u2019s disease. Mov Disord  2022,37(1),25-35","journal-title":"Mov Disord"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","volume":"24","author":"Huang E.J.","year":"2001","unstructured":"Huang E.J.; Reichardt L.F.; Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci  2001,24(1),677-736","journal-title":"Annu Rev Neurosci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"R1053","DOI":"10.1152\/ajpregu.00776.2010","volume":"300","author":"Noble E.E.","year":"2011","unstructured":"Noble E.E.; Billington C.J.; Kotz C.M.; Wang C.; The lighter side of BDNF. Am J Physiol Regul Integr Comp Physiol  2011,300(5),R1053-R1069","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1089\/10430349950016393","volume":"10","author":"Bemelmans A.P.","year":"1999","unstructured":"Bemelmans A.P.; Horellou P.; Pradier L.; Brunet I.; Colin P.; Mallet J.; Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington\u2019s disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther  1999,10(18),2987-2997","journal-title":"Hum Gene Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0306-4522(98)00723-4","volume":"91","author":"P\u00e9rez-Navarro E.","year":"1999","unstructured":"P\u00e9rez-Navarro E.; Alberch J.; Neveu I.; Arenas E.; Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4\/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. Neuroscience  1999,91(4),1257-1264","journal-title":"Neuroscience"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fncel.2014.00254","volume":"8","author":"Baydyuk M.","year":"2014","unstructured":"Baydyuk M.; Xu B.; BDNF signaling and survival of striatal neurons. Front Cell Neurosci  2014,8,254","journal-title":"Front Cell Neurosci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"Zuccato C.","year":"2001","unstructured":"Zuccato C.; Ciammola A.; Rigamonti D.; Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science  2001,293(5529),493-498","journal-title":"Science"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00429-010-0282-9","volume":"215","author":"Saylor A.J.","year":"2010","unstructured":"Saylor A.J.; McGinty J.F.; An intrastriatal brain-derived neurotrophic factor infusion restores striatal gene expression in Bdnf heterozygous mice. Brain Struct Funct  2010,215(2),97-104","journal-title":"Brain Struct Funct"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e64037","DOI":"10.1371\/journal.pone.0064037","volume":"8","author":"Giamp\u00e0 C.","year":"2013","unstructured":"Giamp\u00e0 C.; Montagna E.; Dato C.; Melone M.A.B.; Bernardi G.; Fusco F.R.; Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One  2013,8(5),e64037","journal-title":"PLoS One"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","volume":"19","author":"van Duijn E.","year":"2007","unstructured":"van Duijn E.; Kingma E.M.; van der Mast R.C.; Psychopathology in verified Huntington\u2019s disease gene carriers. J Neuropsychiatry Clin Neurosci  2007,19(4),441-448","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"Bates G.P.","year":"2015","unstructured":"Bates G.P.; Dorsey R.; Gusella J.F.; Huntington disease. Nat Rev Dis Primers  2015,1(1),15005","journal-title":"Nat Rev Dis Primers"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"Roos R.A.C.","year":"2010","unstructured":"Roos R.A.C.; Huntington\u2019s disease: A clinical review. Orphanet J Rare Dis  2010,5(1),40","journal-title":"Orphanet J Rare Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JHD-140092","volume":"3","author":"Nana A.L.","year":"2014","unstructured":"Nana A.L.; Kim E.H.; Thu D.C.V.; Widespread heterogeneous neuronal loss across the cerebral cortex in Huntington\u2019s disease. J Huntingtons Dis  2014,3(1),45-64","journal-title":"J Huntingtons Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1201\/9781003106524-25","author":"Hassanzadeh K.","year":"2022","unstructured":"Hassanzadeh K.; Feligioni M.; Zarei M.; Bioactive peptides in neurodegenerative diseases. In: Bioact pept from food sources, anal funct  2022,391-414","journal-title":"In: Bioact pept from food sources, anal funct"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/00005072-198809000-00003","volume":"47","author":"de la Monte S.M.","year":"1988","unstructured":"de la Monte S.M.; Vonsattel J.P.; Richardson E.P.; Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington\u2019s disease. J Neuropathol Exp Neurol  1988,47(5),516-525","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/00001756-200402090-00030","volume":"15","author":"Kassubek J.","year":"2004","unstructured":"Kassubek J.; Bernhard Landwehrmeyer G.; Ecker D.; Global cerebral atrophy in early stages of Huntington\u02bcs disease: quantitative MRI study. Neuroreport  2004,15(2),363-365","journal-title":"Neuroreport"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1212\/01.WNL.0000138434.68093.67","volume":"63","author":"Fennema-Notestine C.","year":"2004","unstructured":"Fennema-Notestine C.; Archibald S.L.; Jacobson M.W.; in vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology  2004,63(6),989-995","journal-title":"Neurology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1212\/WNL.28.11.1196","volume":"28","author":"Barr A.N.","year":"1978","unstructured":"Barr A.N.; Heinze W.J.; Dobben G.D.; Valvassori G.E.; Sugar O.; Bicaudate index in computerized tomography of Huntington disease and cerebral atrophy. Neurology  1978,28(11),1196-1200","journal-title":"Neurology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"105574","DOI":"10.1016\/j.nbd.2021.105574","volume":"162","author":"Barry J.","year":"2022","unstructured":"Barry J.; Bui M.T.N.; Levine M.S.; Cepeda C.; Synaptic pathology in Huntington\u2019s disease: Beyond the corticostriatal pathway. Neurobiol Dis  2022,162,105574","journal-title":"Neurobiol Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0072-9752(07)01256-0","volume":"89","author":"Vonsattel J.P.G.","year":"2008","unstructured":"Vonsattel J.P.G.; Keller C.; Pilar Amaya M.; Neuropathology of Huntington\u2019s disease. Handb Clin Neurol  2008,89,599-618","journal-title":"Handb Clin Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"Vonsattel J.P.","year":"1985","unstructured":"Vonsattel J.P.; Myers R.H.; Stevens T.J.; Ferrante R.J.; Bird E.D.; Richardson E.P.; Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol  1985,44(6),559-577","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/bs.apha.2014.11.010","volume":"73","author":"Waldvogel H.J.","year":"2015","unstructured":"Waldvogel H.J.; Faull R.L.M.; The diversity of GABA(A) receptor subunit distribution in the normal and Huntington\u2019s disease human brain. Adv Pharmacol  2015,73,223-264","journal-title":"Adv Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0166-2236(87)90120-2","volume":"10","author":"Kowall N.W.","year":"1987","unstructured":"Kowall N.W.; Ferrante R.J.; Martin J.B.; Patterns of cell loss in Huntington\u2019s disease. Trends Neurosci  1987,10(1),24-29","journal-title":"Trends Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/mds.25624","volume":"28","author":"Reiner A.","year":"2013","unstructured":"Reiner A.; Shelby E.; Wang H.; Striatal parvalbuminergic neurons are lost in Huntington\u2019s disease: implications for dystonia. Mov Disord  2013,28(12),1691-1699","journal-title":"Mov Disord"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(88)92073-9","volume":"331","author":"Seto-Ohshima A.","year":"1988","unstructured":"Seto-Ohshima A.; Lawson E.; Emson P.C.; Mountjoy C.Q.; Carrasco L.H.; Loss of matrix calcium-binding protein-containing neurons in Huntington\u2019s disease. Lancet  1988,331(8597),1252-1255","journal-title":"Lancet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0006-8993(90)90866-A","volume":"525","author":"Kiyama H.","year":"1990","unstructured":"Kiyama H.; Seto-Ohshima A.; Emson P.C.; Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington\u2019s disease. Brain Res  1990,525(2),209-214","journal-title":"Brain Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ana.24162","volume":"75","author":"Kim E.H.","year":"2014","unstructured":"Kim E.H.; Thu D.C.V.; Tippett L.J.; Cortical interneuron loss and symptom heterogeneity in Huntington disease. Ann Neurol  2014,75(5),717-727","journal-title":"Ann Neurol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40478-020-0878-0","volume":"8","author":"Crevier-Sorbo G.","year":"2020","unstructured":"Crevier-Sorbo G.; Rymar V.V.; Crevier-Sorbo R.; Sadikot A.F.; Thalamostriatal degeneration contributes to dystonia and cholinergic interneuron dysfunction in a mouse model of Huntington\u2019s disease. Acta Neuropathol Commun  2020,8(1),14","journal-title":"Acta Neuropathol Commun"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nbd.2005.10.009","volume":"22","author":"Picconi B.","year":"2006","unstructured":"Picconi B.; Passino E.; Sgobio C.; Plastic and behavioral abnormalities in experimental Huntington\u2019s disease: A crucial role for cholinergic interneurons. Neurobiol Dis  2006,22(1),143-152","journal-title":"Neurobiol Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1523\/JNEUROSCI.5687-08.2009","volume":"29","author":"Joshi P.R.","year":"2009","unstructured":"Joshi P.R.; Wu N.P.; Andr\u00e9 V.M.; Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci  2009,29(8),2414-2427","journal-title":"J Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0361-9230(01)00611-6","volume":"56","author":"Morton A.J.","year":"2001","unstructured":"Morton A.J.; Faull R.L.M.; Edwardson J.M.; Abnormalities in the synaptic vesicle fusion machinery in Huntington\u2019s disease. Brain Res Bull  2001,56(2),111-117","journal-title":"Brain Res Bull"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/jnr.1244","volume":"66","author":"Cepeda C.","year":"2001","unstructured":"Cepeda C.; Ariano M.A.; Calvert C.R.; NMDA receptor function in mouse models of Huntington disease. J Neurosci Res  2001,66(4),525-539","journal-title":"J Neurosci Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1212\/WNL.0000000000012969","volume":"98","author":"Delva A.","year":"2022","unstructured":"Delva A.; Michiels L.; Koole M.; Van Laere K.; Vandenberghe W.; Synaptic damage and its clinical correlates in people with early Huntington disease: A PET study. Neurology  2022,98(1),e83-e94","journal-title":"Neurology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1523\/JNEUROSCI.3539-10.2011","volume":"31","author":"Andr\u00e9 V.M.","year":"2011","unstructured":"Andr\u00e9 V.M.; Cepeda C.; Fisher Y.E.; Differential electrophysiological changes in striatal output neurons in Huntington\u2019s disease. J Neurosci  2011,31(4),1170-1182","journal-title":"J Neurosci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3233\/JHD-210518","volume":"11","author":"Petersen M.H.","year":"2022","unstructured":"Petersen M.H.; Willert C.W.; Andersen J.V.; Progressive mitochondrial dysfunction of striatal synapses in R6\/2 mouse model of Huntington\u2019s disease. J Huntingtons Dis  2022,11(2),121-140","journal-title":"J Huntingtons Dis"},{"key":"ref=41","first-page":"1073858420972662","volume":"5","author":"Cepeda C.","year":"2020","unstructured":"Cepeda C.; Levine M.S.; Synaptic dysfunction in Huntington\u2019s disease: lessons from genetic animal models. Neurosci  2020,5,1073858420972662","journal-title":"Neurosci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jnc.13658","volume":"138","author":"Foltran R.B.","year":"2016","unstructured":"Foltran R.B.; Diaz S.L.; BDNF isoforms: A round trip ticket between neurogenesis and serotonin? J Neurochem  2016,138(2),204-221","journal-title":"J Neurochem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"12660","DOI":"10.1074\/jbc.M008104200","volume":"276","author":"Mowla S.J.","year":"2001","unstructured":"Mowla S.J.; Farhadi H.F.; Pareek S.; Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem  2001,276(16),12660-12666","journal-title":"J Biol Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"15924","DOI":"10.1073\/pnas.1207767109","volume":"109","author":"Je H.S.","year":"2012","unstructured":"Je H.S.; Yang F.; Ji Y.; Nagappan G.; Hempstead B.L.; Lu B.; Role of pro-brain-derived neurotrophic factor (proBDNF) to mature BDNF conversion in activity-dependent competition at developing neuromuscular synapses. Proc Natl Acad Sci  2012,109(39),15924-15929","journal-title":"Proc Natl Acad Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/jnc.13415","volume":"139","author":"Vafadari B.","year":"2016","unstructured":"Vafadari B.; Salamian A.; Kaczmarek L.; MMP \u20109 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem  2016,139(Suppl. 2),91-114","journal-title":"J Neurochem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1083\/jcb.201201038","volume":"196","author":"Dieni S.","year":"2012","unstructured":"Dieni S.; Matsumoto T.; Dekkers M.; BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. J Cell Biol  2012,196(6),775-788","journal-title":"J Cell Biol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12017-013-8270-x","volume":"16","author":"Yang J.L.","year":"2014","unstructured":"Yang J.L.; Lin Y.T.; Chuang P.C.; Bohr V.A.; Mattson M.P.; BDNF and exercise enhance neuronal DNA repair by stimulating CREB-mediated production of apurinic\/apyrimidinic endonuclease 1. Neuromolecular Med  2014,16(1),161-174","journal-title":"Neuromolecular Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.neuropharm.2013.04.054","volume":"76 Pt C","author":"Deinhardt K","year":"2014","unstructured":"Deinhardt K; Chao MV; Shaping neurons: Long and short range effects of mature and proBDNF signalling upon neuronal structure. Neuropharmacology  2014,76 Pt C(0 0),603-9","journal-title":"Neuropharmacology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.tins.2012.01.003","volume":"35","author":"Nykjaer A.","year":"2012","unstructured":"Nykjaer A.; Willnow T.E.; Sortilin: A receptor to regulate neuronal viability and function. Trends Neurosci  2012,35(4),261-270","journal-title":"Trends Neurosci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JHD-170275","volume":"6","author":"Simmons D.A.","year":"2017","unstructured":"Simmons D.A.; Modulating neurotrophin receptor signaling as a therapeutic strategy for Huntington\u2019s disease. J Huntingtons Dis  2017,6(4),303-325","journal-title":"J Huntingtons Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"15608","DOI":"10.1523\/JNEUROSCI.2581-10.2010","volume":"30","author":"Song W.","year":"2010","unstructured":"Song W.; Volosin M.; Cragnolini A.B.; Hempstead B.L.; Friedman W.J.; ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. J Neurosci  2010,30(46),15608-15615","journal-title":"J Neurosci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12079-013-0200-z","volume":"7","author":"Sandhya V.K.","year":"2013","unstructured":"Sandhya V.K.; Raju R.; Verma R.; A network map of BDNF\/TRKB and BDNF\/p75NTR signaling system. J Cell Commun Signal  2013,7(4),301-307","journal-title":"J Cell Commun Signal"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.3390\/ijms21207777","volume":"21","author":"Colucci-D\u2019Amato L.","year":"2020","unstructured":"Colucci-D\u2019Amato L.; Speranza L.; Volpicelli F.; Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci  2020,21(20),7777","journal-title":"Int J Mol Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.celrep.2014.10.016","volume":"9","author":"Panja D.","year":"2014","unstructured":"Panja D.; Kenney J.W.; D\u2019Andrea L.; Two-stage translational control of dentate gyrus LTP consolidation is mediated by sustained BDNF-TrkB signaling to MNK. Cell Rep  2014,9(4),1430-1445","journal-title":"Cell Rep"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2017.03.029","volume":"1665","author":"Zhao H.","year":"2017","unstructured":"Zhao H.; Alam A.; San C.Y.; Molecular mechanisms of brain-derived neurotrophic factor in neuro-protection: Recent developments. Brain Res  2017,1665,1-21","journal-title":"Brain Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nrn2738","volume":"10","author":"Minichiello L.","year":"2009","unstructured":"Minichiello L.; TrkB signalling pathways in LTP and learning. Nat Rev Neurosci  2009,10(12),850-860","journal-title":"Nat Rev Neurosci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/cm.21312","volume":"73","author":"Gonzalez A.","year":"2016","unstructured":"Gonzalez A.; Moya-Alvarado G.; Gonzalez-Billaut C.; Bronfman F.C.; Cellular and molecular mechanisms regulating neuronal growth by brain\u2010derived neurotrophic factor. Cytoskeleton  2016,73(10),612-628","journal-title":"Cytoskeleton"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"11300","DOI":"10.1523\/JNEUROSCI.2270-05.2005","volume":"25","author":"Jaworski J.","year":"2005","unstructured":"Jaworski J.; Spangler S.; Seeburg D.P.; Hoogenraad C.C.; Sheng M.; Control of dendritic arborization by the phosphoinositide-3\u2032-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci  2005,25(49),11300-11312","journal-title":"J Neurosci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1743-6109.2006.00292.x","volume":"3","author":"Lin G.","year":"2006","unstructured":"Lin G.; Bella A.J.; Lue T.F.; Lin C.S.; Brain-derived neurotrophic factor (BDNF) acts primarily via the JAK\/STAT pathway to promote neurite growth in the major pelvic ganglion of the rat: part 2. J Sex Med  2006,3(5),821-829","journal-title":"J Sex Med"},{"key":"ref=60","first-page":"65","volume":"5","author":"Schulte J.","year":"2011","unstructured":"Schulte J.; Littleton J.T.; The biological function of the Huntingtin protein and its relevance to Huntington\u2019s Disease pathology. Curr Trends Neurol  2011,5,65-78","journal-title":"Curr Trends Neurol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5607\/en.2018.27.3.217","volume":"27","author":"Park H.","year":"2018","unstructured":"Park H.; Cortical axonal secretion of BDNF in the striatum is disrupted in the mutant-huntingtin knock-in mouse model of huntington\u2019s disease. Exp Neurobiol  2018,27(3),217-225","journal-title":"Exp Neurobiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/39885","volume":"389","author":"Altar C.A.","year":"1997","unstructured":"Altar C.A.; Cai N.; Bliven T.; Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature  1997,389(6653),856-860","journal-title":"Nature"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"Gauthier L.R.","year":"2004","unstructured":"Gauthier L.R.; Charrin B.C.; Borrell-Pag\u00e8s M.; Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell  2004,118(1),127-138","journal-title":"Cell"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1523\/JNEUROSCI.2033-12.2013","volume":"33","author":"Liot G.","year":"2013","unstructured":"Liot G.; Zala D.; Pla P.; Mottet G.; Piel M.; Saudou F.; Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci  2013,33(15),6298-6309","journal-title":"J Neurosci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","volume":"24","author":"Canals J.M.","year":"2004","unstructured":"Canals J.M.; Pineda J.R.; Torres-Peraza J.F.; Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington\u2019s disease. J Neurosci  2004,24(35),7727-7739","journal-title":"J Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.phrs.2005.01.001","volume":"52","author":"Zuccato C.","year":"2005","unstructured":"Zuccato C.; Liber D.; Ramos C.; Progressive loss of BDNF in a mouse model of Huntington\u2019s disease and rescue by BDNF delivery. Pharmacol Res  2005,52(2),133-139","journal-title":"Pharmacol Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1471-4159.2005.03047.x","volume":"93","author":"Pineda J.R.","year":"2005","unstructured":"Pineda J.R.; Canals J.M.; Bosch M.; Brain\u2010derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington\u2019s disease. J Neurochem  2005,93(5),1057-1068","journal-title":"J Neurochem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1481.e1","DOI":"10.1016\/j.neurobiolaging.2011.11.030","volume":"33","author":"Griffioen K.J.","year":"2012","unstructured":"Griffioen K.J.; Wan R.; Brown T.R.; Aberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington\u2019s disease. Neurobiol Aging  2012,33(7),1481.e1-1481.e5","journal-title":"Neurobiol Aging"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"16976","DOI":"10.1038\/s41598-018-34883-w","volume":"8","author":"Yu C.","year":"2018","unstructured":"Yu C.; Li C.H.; Chen S.; Yoo H.; Qin X.; Park H.; Decreased BDNF release in cortical neurons of a knock-in mouse model of Huntington\u2019s disease. Sci Rep  2018,8(1),16976","journal-title":"Sci Rep"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcn.2008.04.012","volume":"39","author":"Conforti P.","year":"2008","unstructured":"Conforti P.; Ramos C.; Apostol B.L.; Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington\u2019s disease: Restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci  2008,39(1),1-7","journal-title":"Mol Cell Neurosci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1601-183X.2012.00858.x","volume":"12","author":"Samadi P.","year":"2013","unstructured":"Samadi P.; Boutet A.; Rymar V.V.; Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6\/2 mouse model of Huntington\u2019s disease. Genes Brain Behav  2013,12(1),108-124","journal-title":"Genes Brain Behav"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1523\/JNEUROSCI.4454-03.2004","volume":"24","author":"Di\u00f3genes M.J.","year":"2004","unstructured":"Di\u00f3genes M.J.; Fernandes C.C.; Sebasti\u00e3o A.M.; Ribeiro J.A.; Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci  2004,24(12),2905-2913","journal-title":"J Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11302-007-9066-y","volume":"3","author":"Potenza R.L.","year":"2007","unstructured":"Potenza R.L.; Tebano M.T.; Martire A.; Adenosine A2A receptors modulate BDNF both in normal conditions and in experimental models of Huntington\u2019s disease. Purinergic Signal  2007,3(4),333-338","journal-title":"Purinergic Signal"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1371\/journal.pone.0000238","volume":"2","author":"Seo H.","year":"2007","unstructured":"Seo H.; Sonntag K.C.; Kim W.; Cattaneo E.; Isacson O.; Proteasome activator enhances survival of Huntington\u2019s disease neuronal model cells. PLoS One  2007,2(2),e238","journal-title":"PLoS One"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.20207","volume":"56","author":"Seo H.","year":"2004","unstructured":"Seo H.; Sonntag K.C.; Isacson O.; Generalized brain and skin proteasome inhibition in Huntington\u2019s disease. Ann Neurol  2004,56(3),319-328","journal-title":"Ann Neurol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/hmg\/ddn211","volume":"17","author":"Seo H.","year":"2008","unstructured":"Seo H.; Kim W.; Isacson O.; Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II\/III in YAC72 and R6\/2 transgenic mice partially model Huntington\u2019s disease patients. Hum Mol Genet  2008,17(20),3144-3153","journal-title":"Hum Mol Genet"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fncel.2016.00037","volume":"10","author":"Nguyen K.Q.","year":"2016","unstructured":"Nguyen K.Q.; Rymar V.V.; Sadikot A.F.; Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6\/2 mouse model of huntington\u2019s disease. Front Cell Neurosci  2016,10,37","journal-title":"Front Cell Neurosci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.nbd.2015.08.008","volume":"82","author":"Ma Q.","year":"2015","unstructured":"Ma Q.; Yang J.; Li T.; Milner T.A.; Hempstead B.L.; Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington\u2019s disease. Neurobiol Dis  2015,82,466-477","journal-title":"Neurobiol Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2014.05.032","volume":"83","author":"Plotkin J.L.","year":"2014","unstructured":"Plotkin J.L.; Day M.; Peterson J.D.; Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington\u2019s disease. Neuron  2014,83(1),178-188","journal-title":"Neuron"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1038\/cddis.2013.116","volume":"4","author":"Brito V.","year":"2013","unstructured":"Brito V.; Puigdell\u00edvol M.; Giralt A.; del Toro D.; Alberch J.; Gin\u00e9s S.; Imbalance of p75NTR\/TrkB protein expression in Huntington\u2019s disease: implication for neuroprotective therapies. Cell Death Dis  2013,4(4),e595-5","journal-title":"Cell Death Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1212\/01.wnl.0000175977.57661.b1","volume":"65","author":"Alberch J.","year":"2005","unstructured":"Alberch J.; L\u00f3pez M.; Badenas C.; Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. Neurology  2005,65(6),964-965","journal-title":"Neurology"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.nbd.2006.07.002","volume":"24","author":"Di Maria E.","year":"2006","unstructured":"Di Maria E.; Marasco A.; Tartari M.; No evidence of association between BDNF gene variants and age-at-onset of Huntington\u2019s disease. Neurobiol Dis  2006,24(2),274-279","journal-title":"Neurobiol Dis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.nbd.2006.07.008","volume":"24","author":"Kishikawa S.","year":"2006","unstructured":"Kishikawa S.; Li J.L.; Gillis T.; Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington\u2019s disease. Neurobiol Dis  2006,24(2),280-285","journal-title":"Neurobiol Dis"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2350-7-79","volume":"7","author":"Mai M.","year":"2006","unstructured":"Mai M.; Akkad A.D.; Wieczorek S.; No association between polymorphisms in the BDNF gene and age at onset in Huntington disease. BMC Med Genet  2006,7(1),79","journal-title":"BMC Med Genet"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fnmol.2019.00335","volume":"12","author":"Gutierrez A.","year":"2020","unstructured":"Gutierrez A.; Corey-Bloom J.; Thomas E.A.; Desplats P.; Evaluation of biochemical and epigenetic measures of peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in Huntington\u2019s disease patients. Front Mol Neurosci  2020,12,335","journal-title":"Front Mol Neurosci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1750-3639.2007.00111.x","volume":"18","author":"Zuccato C.","year":"2008","unstructured":"Zuccato C.; Marullo M.; Conforti P.; MacDonald M.E.; Tartari M.; Cattaneo E.; Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington\u2019s disease. Brain Pathol  2008,18(2),225-238","journal-title":"Brain Pathol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2047-9158-3-17","volume":"3","author":"M\u00fcller S.","year":"2014","unstructured":"M\u00fcller S.; In silico analysis of regulatory networks underlines the role of miR-10b-5p and its target BDNF in huntington\u2019s disease. Transl Neurodegener  2014,3(1),17","journal-title":"Transl Neurodegener"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0006-8993(00)02237-X","volume":"866","author":"Ferrer I.","year":"2000","unstructured":"Ferrer I.; Goutan E.; Mar\u00edn C.; Rey M.J.; Ribalta T.; Brain-derived neurotrophic factor in Huntington disease. Brain Res  2000,866(1-2),257-261","journal-title":"Brain Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ajmg.b.30501","volume":"144B","author":"Ciammola A.","year":"2007","unstructured":"Ciammola A.; Sassone J.; Cannella M.; Low brain\u2010derived neurotrophic factor (BDNF) levels in serum of Huntington\u2019s disease patients. Am J Med Genet B Neuropsychiatr Genet  2007,144B(4),574-577","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.3390\/jcm10215181","volume":"10","author":"Plinta K.","year":"2021","unstructured":"Plinta K.; Plewka A.; Pawlicki K.; The utility of bdnf detection in assessing severity of huntington\u2019s disease. J Clin Med  2021,10(21),5181","journal-title":"J Clin Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"e22966","DOI":"10.1371\/journal.pone.0022966","volume":"6","author":"Zuccato C.","year":"2011","unstructured":"Zuccato C.; Marullo M.; Vitali B.; Brain-derived neurotrophic factor in patients with Huntington\u2019s disease. PLoS One  2011,6(8),e22966","journal-title":"PLoS One"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1038\/s41598-021-83000-x","volume":"11","author":"Ou Z.Y.A.","year":"2021","unstructured":"Ou Z.Y.A.; Byrne L.M.; Rodrigues F.B.; Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington\u2019s disease. Sci Rep  2021,11(1),3481","journal-title":"Sci Rep"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.12871\/00039829201813","volume":"156","author":"Betti L.","year":"2018","unstructured":"Betti L.; Palego L.; Unti E.; Brain-derived neurotrophic factor (BDNF) and serotonin transporter (SERT) in platelets of patients with mild Huntington\u2019s disease: relationships with social cognition symptoms. Arch Ital Biol  2018,156(1),27-39","journal-title":"Arch Ital Biol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1750-1326-5-22","volume":"5","author":"Ma B.","year":"2010","unstructured":"Ma B.; Culver B.P.; Baj G.; Tongiorgi E.; Chao M.V.; Tanese N.; Localization of BDNF mRNA with the Huntington\u2019s disease protein in rat brain. Mol Neurodegener  2010,5(1),22","journal-title":"Mol Neurodegener"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000375447","volume":"15","author":"Silva A.","year":"2015","unstructured":"Silva A.; Naia L.; Dominguez A.; Overexpression of BDNF and full-length Trkb receptor ameliorate striatal neural survival in Huntington\u2019s disease. Neurodegener Dis  2015,15(4),207-218","journal-title":"Neurodegener Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"12748","DOI":"10.1523\/JNEUROSCI.3873-06.2006","volume":"26","author":"del Toro D.","year":"2006","unstructured":"del Toro D.; Canals J.M.; Gin\u00e9s S.; Kojima M.; Egea G.; Alberch J.; Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J Neurosci  2006,26(49),12748-12757","journal-title":"J Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"13662","DOI":"10.1523\/JNEUROSCI.4144-08.2008","volume":"28","author":"Her L.S.","year":"2008","unstructured":"Her L.S.; Goldstein L.S.B.; Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci  2008,28(50),13662-13672","journal-title":"J Neurosci"},{"key":"ref=98","first-page":"237","volume":"25","author":"Numakawa T.","year":"2010","unstructured":"Numakawa T.; Suzuki S.; Kumamaru E.; Adachi N.; Richards M.; Kunugi H.; BDNF function and intracellular signaling in neurons. Histol Histopathol  2010,25(2),237-258","journal-title":"Histol Histopathol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/biology12020157","volume":"12","author":"Maloney M.T.","year":"2023","unstructured":"Maloney M.T.; Wang W.; Bhowmick S.; Failure to thrive: Impaired BDNF transport along the cortical-striatal axis in mouse Q140 neurons of Huntington\u2019s disease. Biology (Basel)  2023,12(2),157","journal-title":"Biology (Basel)"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.18632\/aging.202603","volume":"13","author":"Zhou Z.","year":"2021","unstructured":"Zhou Z.; Zhong S.; Zhang R.; Functional analysis of brain derived neurotrophic factor (BDNF) in Huntington\u2019s disease. Aging  2021,13(4),6103-6114","journal-title":"Aging"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1007\/s12035-018-0890-6","volume":"55","author":"da Fons\u00eaca V.S.","year":"2018","unstructured":"da Fons\u00eaca V.S.; da Silva Colla A.R.; de Paula Nascimento-Castro C.; Brain-derived neurotrophic factor prevents depressive-like behaviors in early-symptomatic YAC128 Huntington\u2019s disease mice. Mol Neurobiol  2018,55(9),7201-7215","journal-title":"Mol Neurobiol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/gt.2015.113","volume":"23","author":"Connor B.","year":"2016","unstructured":"Connor B.; Sun Y.; von Hieber D.; Tang S.K.; Jones K.S.; Maucksch C.; AAV1\/2-mediated BDNF gene therapy in a transgenic rat model of Huntington\u2019s disease. Gene Ther  2016,23(3),283-295","journal-title":"Gene Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10571-011-9725-y","volume":"31","author":"Arregui L.","year":"2011","unstructured":"Arregui L.; Ben\u00edtez J.A.; Razgado L.F.; Vergara P.; Segovia J.; Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington\u2019s disease delays the onset of the motor phenotype. Cell Mol Neurobiol  2011,31(8),1229-1243","journal-title":"Cell Mol Neurobiol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ymthe.2004.02.016","volume":"9","author":"Kells A.P.","year":"2004","unstructured":"Kells A.P.; Fong D.M.; Dragunow M.; During M.J.; Young D.; Connor B.; AAV-Mediated gene delivery of BDNF or GDNF is neuroprotective in a model of huntington disease. Mol Ther  2004,9(5),682-688","journal-title":"Mol Ther"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/gt.2010.71","volume":"17","author":"Giralt A.","year":"2010","unstructured":"Giralt A.; Friedman H.C.; Caneda-Ferr\u00f3n B.; BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington\u2019s disease. Gene Ther  2010,17(10),1294-1308","journal-title":"Gene Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1109967","DOI":"10.1155\/2023\/1109967","volume":"2023","author":"Liang X.S.","year":"2023","unstructured":"Liang X.S.; Sun Z.W.; Thomas A.M.; Li S.; Mesenchymal stem cell therapy for Huntington disease: A meta-analysis. Stem Cells Int  2023,2023,1109967","journal-title":"Stem Cells Int"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbr.2010.05.023","volume":"214","author":"Dey N.D.","year":"2010","unstructured":"Dey N.D.; Bombard M.C.; Roland B.P.; Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington\u2019s disease. Behav Brain Res  2010,214(2),193-200","journal-title":"Behav Brain Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/mt.2016.12","volume":"24","author":"Pollock K.","year":"2016","unstructured":"Pollock K.; Dahlenburg H.; Nelson H.; Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington\u2019s disease mouse models. Mol Ther  2016,24(5),965-977","journal-title":"Mol Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12035-011-8219-8","volume":"45","author":"Olson S.D.","year":"2012","unstructured":"Olson S.D.; Pollock K.; Kambal A.; Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington\u2019s disease. Mol Neurobiol  2012,45(1),87-98","journal-title":"Mol Neurobiol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1046\/j.1471-4159.2000.0752190.x","volume":"75","author":"P\u00e9rez-Navarro E.","year":"2000","unstructured":"P\u00e9rez-Navarro E.; Canudas A.M.; \u00c5kerud P.; Alberch J.; Arenas E.; Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4\/5 prevent the death of striatal projection neurons in a rodent model of Huntington\u2019s disease. J Neurochem  2000,75(5),2190-2199","journal-title":"J Neurochem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.stemcr.2016.08.018","volume":"7","author":"Zimmermann T.","year":"2016","unstructured":"Zimmermann T.; Remmers F.; Lutz B.; Leschik J.; ESC-derived BDNF-overexpressing neural progenitors differentially promote recovery in Huntington\u2019s disease models by enhanced striatal differentiation. Stem Cell Reports  2016,7(4),693-706","journal-title":"Stem Cell Reports"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5607\/en20011","volume":"29","author":"Kim H.S.","year":"2020","unstructured":"Kim H.S.; Jeon I.; Noh J.E.; Intracerebral transplantation of BDNF-overexpressing human neural stem cells (HB1.F3.BDNF) promotes migration, differentiation and functional recovery in a rodent model of Huntington\u2019s disease. Exp Neurobiol  2020,29(2),130-137","journal-title":"Exp Neurobiol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1471-4159.2007.05137.x","volume":"105","author":"Gharami K.","year":"2008","unstructured":"Gharami K.; Xie Y.; An J.J.; Tonegawa S.; Xu B.; Brain\u2010derived neurotrophic factor over\u2010expression in the forebrain ameliorates Huntington\u2019s disease phenotypes in mice. J Neurochem  2008,105(2),369-379","journal-title":"J Neurochem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","volume":"30","author":"Xie Y.","year":"2010","unstructured":"Xie Y.; Hayden M.R.; Xu B.; BDNF overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice. J Neurosci  2010,30(44),14708-14718","journal-title":"J Neurosci"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/chemse\/bjv076","volume":"41","author":"Smail S.","year":"2016","unstructured":"Smail S.; Bahga D.; McDole B.; Guthrie K.; Increased olfactory bulb BDNF expression does not rescue deficits in olfactory neurogenesis in the Huntington\u2019s disease R6\/2 mouse. Chem Senses  2016,41(3),221-232","journal-title":"Chem Senses"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1326-6-71","volume":"6","author":"Giralt A.","year":"2011","unstructured":"Giralt A.; Carret\u00f3n O.; Lao-Peregrin C.; Mart\u00edn E.D.; Alberch J.; Conditional BDNF release under pathological conditions improves Huntington\u2019s disease pathology by delaying neuronal dysfunction. Mol Neurodegener  2011,6(1),71","journal-title":"Mol Neurodegener"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1523\/JNEUROSCI.5113-06.2007","volume":"27","author":"Lynch G.","year":"2007","unstructured":"Lynch G.; Kramar E.A.; Rex C.S.; Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington\u2019s disease. J Neurosci  2007,27(16),4424-4434","journal-title":"J Neurosci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jnc.12177","volume":"125","author":"Martire A.","year":"2013","unstructured":"Martire A.; Pepponi R.; Domenici M.R.; Ferrante A.; Chiodi V.; Popoli P.; BDNF prevents NMDA \u2010induced toxicity in models of Huntington\u2019s disease: the effects are genotype specific and adenosine A 2A receptor is involved. J Neurochem  2013,125(2),225-235","journal-title":"J Neurochem"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/jnr.24507","volume":"97","author":"Torres-Cruz F.M.","year":"2019","unstructured":"Torres-Cruz F.M.; Mendoza E.; Vivar-Cort\u00e9s I.C.; Garc\u00eda-Sierra F.; Hern\u00e1ndez-Echeagaray E.; Do BDNF and NT\u20104\/5 exert synergistic or occlusive effects on corticostriatal transmission in a male mouse model of Huntington\u2019s disease? J Neurosci Res  2019,97(12),1665-1677","journal-title":"J Neurosci Res"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","volume":"95","author":"Van Raamsdonk J.M.","year":"2005","unstructured":"Van Raamsdonk J.M.; Pearson J.; Bailey C.D.C.; Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem  2005,95(1),210-220","journal-title":"J Neurochem"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1172\/JCI27607","volume":"116","author":"Borrell-Pag\u00e8s M.","year":"2006","unstructured":"Borrell-Pag\u00e8s M.; Canals J.M.; Cordeli\u00e8res F.P.; Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest  2006,116(5),1410-1424","journal-title":"J Clin Invest"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","volume":"210","author":"Peng Q.","year":"2008","unstructured":"Peng Q.; Masuda N.; Jiang M.; The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington\u2019s disease mouse model. Exp Neurol  2008,210(1),154-163","journal-title":"Exp Neurol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1073\/pnas.0811228106","volume":"106","author":"Simmons D.A.","year":"2009","unstructured":"Simmons D.A.; Rex C.S.; Palmer L.; Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington\u2019s disease knockin mice. Proc Natl Acad Sci  2009,106(12),4906-4911","journal-title":"Proc Natl Acad Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.brainres.2012.07.026","volume":"1473","author":"Reiner A.","year":"2012","unstructured":"Reiner A.; Wang H.B.; Del Mar N.; Sakata K.; Yoo W.; Deng Y.P.; BDNF may play a differential role in the protective effect of the mGluR2\/3 agonist LY379268 on striatal projection neurons in R6\/2 Huntington\u2019s disease mice. Brain Res  2012,1473,161-172","journal-title":"Brain Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"136180","DOI":"10.1016\/j.neulet.2021.136180","volume":"763","author":"Wang H.","year":"2021","unstructured":"Wang H.; Del Mar N.; Deng Y.; Reiner A.; Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2\/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6\/2 Huntington\u2019s disease mice. Neurosci Lett  2021,763,136180","journal-title":"Neurosci Lett"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"110288","DOI":"10.1016\/j.cbi.2022.110288","volume":"369","author":"Ibrahim H.I.","year":"2023","unstructured":"Ibrahim H.I.; Rabie M.A.; Mohamed R.A.; Nassar N.N.; Adenosine A1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington\u2019s disease via stimulation of TrKB\/PI3K\/Akt\/CREB\/BDNF pathway in 3-nitropropionic acid rat model. Chem Biol Interact  2023,369,110288","journal-title":"Chem Biol Interact"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"E5655","DOI":"10.1073\/pnas.1603020113","volume":"113","author":"Zhao X.","year":"2016","unstructured":"Zhao X.; Chen X.Q.; Han E.; TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington\u2019s disease. Proc Natl Acad Sci  2016,113(38),E5655-E5664","journal-title":"Proc Natl Acad Sci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"120569","DOI":"10.1016\/j.lfs.2022.120569","volume":"300","author":"El-Shamarka M.E.S.","year":"2022","unstructured":"El-Shamarka M.E.S.; El-Sahar A.E.; Saad M.A.; Assaf N.; Sayed R.H.; Inosine attenuates 3-nitropropionic acid-induced Huntington\u2019s disease-like symptoms in rats via the activation of the A2AR\/BDNF\/TrKB\/ERK\/CREB signaling pathway. Life Sci  2022,300,120569","journal-title":"Life Sci"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/hmg\/ddy153","volume":"27","author":"Di Pardo A.","year":"2018","unstructured":"Di Pardo A.; Castaldo S.; Amico E.; Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington\u2019s disease. Hum Mol Genet  2018,27(14),2490-2501","journal-title":"Hum Mol Genet"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","volume":"33","author":"Simmons D.A.","year":"2013","unstructured":"Simmons D.A.; Belichenko N.P.; Yang T.; A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington\u2019s disease. J Neurosci  2013,33(48),18712-18727","journal-title":"J Neurosci"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1093\/hmg\/ddt098","volume":"22","author":"Jiang M.","year":"2013","unstructured":"Jiang M.; Peng Q.; Liu X.; Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington\u2019s disease. Hum Mol Genet  2013,22(12),2462-2470","journal-title":"Hum Mol Genet"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jnc.12348","volume":"127","author":"Conforti P.","year":"2013","unstructured":"Conforti P.; Zuccato C.; Gaudenzi G.; Binding of the repressor complex REST\u2010 mSIN 3b by small molecules restores neuronal gene transcription in Huntington\u2019s disease models. J Neurochem  2013,127(1),22-35","journal-title":"J Neurochem"},{"key":"ref=133","first-page":"4920","volume":"25","author":"Simmons D.A.","year":"2016","unstructured":"Simmons D.A.; Belichenko N.P.; Ford E.C.; A small molecule p75NTR ligand normalizes signalling and reduces Huntington\u2019s disease phenotypes in R6\/2 and BACHD mice. Hum Mol Genet  2016,25(22),4920-4938","journal-title":"Hum Mol Genet"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1756-6606-2-33","volume":"2","author":"Pineda J.R.","year":"2009","unstructured":"Pineda J.R.; Pardo R.; Zala D.; Yu H.; Humbert S.; Saudou F.; Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington\u2019s disease. Mol Brain  2009,2(1),33","journal-title":"Mol Brain"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.expneurol.2016.08.012","volume":"285","author":"Reick C","year":"2016","unstructured":"Reick C; Ellrichmann G; Tsai T; Expression of brain-derived neurotrophic factor in astrocytes : Beneficial effects of glatiramer 402 Current Neuropharmacology, 2025, Vol. 23, No. 4 Azman and Zakaria acetate in the R6\/2 and YAC128 mouse models of Huntington\u2019s disease. Exp Neurol  2016,285(Pt A),12-23","journal-title":"Exp Neurol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.brainres.2017.08.013","volume":"1673","author":"Corey-Bloom J.","year":"2017","unstructured":"Corey-Bloom J.; Aikin A.M.; Gutierrez A.M.; Nadhem J.S.; Howell T.L.; Thomas E.A.; Beneficial effects of glatiramer acetate in Huntington\u2019s disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res  2017,1673,102-110","journal-title":"Brain Res"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s13311-019-00805-5","volume":"17","author":"Sayed N.H.","year":"2020","unstructured":"Sayed N.H.; Fathy N.; Kortam M.A.; Rabie M.A.; Mohamed A.F.; Kamel A.S.; Vildagliptin attenuates Huntington\u2019s disease through activation of GLP-1 receptor\/PI3K\/Akt\/BDNF pathway in 3-nitropropionic acid rat model. Neurotherapeutics  2020,17(1),252-268","journal-title":"Neurotherapeutics"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10787-020-00787-3","volume":"29","author":"Saroj P.","year":"2021","unstructured":"Saroj P.; Bansal Y.; Singh R.; Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington\u2019s disease through inhibition of NF-\u03baB mediated neuroinflammatory markers and activation of cAMP\/CREB\/BDNF signaling pathway. Inflammopharmacology  2021,29(2),499-511","journal-title":"Inflammopharmacology"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.3390\/ijms21093079","volume":"21","author":"Patnaik A.","year":"2020","unstructured":"Patnaik A.; Spiombi E.; Frasca A.; Landsberger N.; Zagrebelsky M.; Korte M.; Fingolimod modulates dendritic architecture in a BDNF-dependent manner. Int J Mol Sci  2020,21(9),3079","journal-title":"Int J Mol Sci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","volume":"23","author":"Di Pardo A.","year":"2014","unstructured":"Di Pardo A.; Amico E.; Favellato M.; FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet  2014,23(9),2251-2265","journal-title":"Hum Mol Genet"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","volume":"24","author":"Miguez A.","year":"2014","unstructured":"Miguez A.; Garc\u00eda G.; Brito V.I.; Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington\u2019s disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum Mol Genet  2014,24(17),4958-4970","journal-title":"Hum Mol Genet"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","volume":"24","author":"Miguez A.","year":"2015","unstructured":"Miguez A.; Garc\u00eda-D\u00edaz Barriga G.; Brito V.; Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington\u2019s disease by preventing p75 NTR up-regulation and astrocyte-mediated inflammation. Hum Mol Genet  2015,24(17),4958-4970","journal-title":"Hum Mol Genet"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuint.2009.01.018","volume":"54","author":"Hutchinson A.J.","year":"2009","unstructured":"Hutchinson A.J.; Chou C.L.; Israel D.D.; Xu W.; Regan J.W.; Activation of EP2 prostanoid receptors in human glial cell lines stimulates the secretion of BDNF. Neurochem Int  2009,54(7),439-446","journal-title":"Neurochem Int"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nbd.2015.09.001","volume":"95","author":"Anglada-Huguet M.","year":"2016","unstructured":"Anglada-Huguet M.; Vidal-Sancho L.; Giralt A.; Garc\u00eda-D\u00edaz Barriga G.; Xifr\u00f3 X.; Alberch J.; Prostaglandin E2 EP2 activation reduces memory decline in R6\/1 mouse model of Huntington\u2019s disease by the induction of BDNF-dependent synaptic plasticity. Neurobiol Dis  2016,95,22-34","journal-title":"Neurobiol Dis"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nbd.2019.05.009","volume":"129","author":"Eddings C.R.","year":"2019","unstructured":"Eddings C.R.; Arbez N.; Akimov S.; Geva M.; Hayden M.R.; Ross C.A.; Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis  2019,129,118-129","journal-title":"Neurobiol Dis"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1093\/brain\/awu107","volume":"137","author":"Francardo V.","year":"2014","unstructured":"Francardo V.; Bez F.; Wieloch T.; Nissbrandt H.; Ruscher K.; Cenci M.A.; Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain  2014,137(7),1998-2014","journal-title":"Brain"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41419-019-1451-2","volume":"10","author":"Ionescu A.","year":"2019","unstructured":"Ionescu A.; Gradus T.; Altman T.; Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model. Cell Death Dis  2019,10(3),210","journal-title":"Cell Death Dis"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s13311-021-01022-9","volume":"18","author":"Naia L.","year":"2021","unstructured":"Naia L.; Ly P.; Mota S.I.; The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease models. Neurotherapeutics  2021,18(2),1017-1038","journal-title":"Neurotherapeutics"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","volume":"97","author":"Ryskamp D","year":"2017","unstructured":"Ryskamp D; Wu J; Geva M; The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis  2017,97(Pt A),46-59","journal-title":"Neurobiol Dis"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.nbd.2018.12.022","volume":"124","author":"Ryskamp D.","year":"2019","unstructured":"Ryskamp D.; Wu L.; Wu J.; Pridopidine stabilizes mushroom spines in mouse models of Alzheimer\u2019s disease by acting on the sigma-1 receptor. Neurobiol Dis  2019,124,489-504","journal-title":"Neurobiol Dis"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","volume":"25","author":"Geva M.","year":"2016","unstructured":"Geva M.; Kusko R.; Soares H.; Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet  2016,25(18),3975-3987","journal-title":"Hum Mol Genet"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/jcmm.12604","volume":"19","author":"Squitieri F.","year":"2015","unstructured":"Squitieri F.; Di Pardo A.; Favellato M.; Amico E.; Maglione V.; Frati L.; Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model. J Cell Mol Med  2015,19(11),2540-2548","journal-title":"J Cell Mol Med"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"105857","DOI":"10.1016\/j.nbd.2022.105857","volume":"173","author":"Lenoir S.","year":"2022","unstructured":"Lenoir S.; Lahaye R.A.; Vitet H.; Pridopidine rescues BDNF\/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model. Neurobiol Dis  2022,173,105857","journal-title":"Neurobiol Dis"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jns.2011.12.014","volume":"315","author":"Tasset I.","year":"2012","unstructured":"Tasset I.; S\u00e1nchez-L\u00f3pez F.; Ag\u00fcera E.; NGF and nitrosative stress in patients with Huntington\u2019s disease. J Neurol Sci  2012,315(1-2),133-136","journal-title":"J Neurol Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11064-005-6874-8","volume":"30","author":"Calabrese V.","year":"2005","unstructured":"Calabrese V.; Colombrita C.; Guagliano E.; Protective effect of carnosine during nitrosative stress in astroglial cell cultures. Neurochem Res  2005,30(6-7),797-807","journal-title":"Neurochem Res"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/jnr.21665","volume":"86","author":"Mancuso C.","year":"2008","unstructured":"Mancuso C.; Capone C.; Ranieri S.C.; Bilirubin as an endogenous modulator of neurotrophin redox signaling. J Neurosci Res  2008,86(10),2235-2249","journal-title":"J Neurosci Res"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"15272","DOI":"10.3390\/ijms232315272","volume":"23","author":"Tucci P.","year":"2022","unstructured":"Tucci P.; Lattanzi R.; Severini C.; Saso L.; Nrf2 pathway in huntington\u2019s disease (hd): What is its role? Int J Mol Sci  2022,23(23),15272","journal-title":"Int J Mol Sci"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.3390\/ijms21113893","volume":"21","author":"Di Rosa G.","year":"2020","unstructured":"Di Rosa G.; Brunetti G.; Scuto M.; Healthspan enhancement by olive polyphenols in C. elegans wild type and Parkinson\u2019s models. Int J Mol Sci  2020,21(11),3893","journal-title":"Int J Mol Sci"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fphar.2015.00305","volume":"6","author":"Catino S.","year":"2016","unstructured":"Catino S.; Paciello F.; Miceli F.; Ferulic acid regulates the Nrf2\/heme oxygenase-1 system and counteracts trimethyltin-induced neuronal damage in the human neuroblastoma cell line SH-SY5Y. Front Pharmacol  2016,6,305","journal-title":"Front Pharmacol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.freeradbiomed.2020.10.022","volume":"162","author":"Moretti D.","year":"2021","unstructured":"Moretti D.; Tambone S.; Cerretani M.; NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington\u2019s disease mouse model. Free Radic Biol Med  2021,162,243-254","journal-title":"Free Radic Biol Med"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s10787-022-01004-z","volume":"30","author":"Ibrahim W.W.","year":"2022","unstructured":"Ibrahim W.W.; Abdel Rasheed N.O.; Diapocynin neuroprotective effects in 3-nitropropionic acid Huntington\u2019s disease model in rats: emphasis on Sirt1\/Nrf2 signaling pathway. Inflammopharmacology  2022,30(5),1745-1758","journal-title":"Inflammopharmacology"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"113721","DOI":"10.1016\/j.fct.2023.113721","volume":"175","author":"Gendy A.M.","year":"2023","unstructured":"Gendy A.M.; Soubh A.; Elnagar M.R.; New insights into the role of berberine against 3-nitropropionic acid-induced striatal neurotoxicity: Possible role of BDNF-TrkB-PI3K\/Akt and NF-\u03baB signaling. Food Chem Toxicol  2023,175,113721","journal-title":"Food Chem Toxicol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"109771","DOI":"10.1016\/j.intimp.2023.109771","volume":"116","author":"Mohamed O.E.","year":"2023","unstructured":"Mohamed O.E.; Abdallah D.M.; Fayez A.M.; Mohamed R.A.; El-Abhar H.S.; Morin post-treatment surpassed calpeptin in ameliorating] 3-NP-induced cortical neurotoxicity via modulation of glutamate\/calpain axis, Kidins220, and BDNF\/TrkB\/AKT\/CREB trajectory. Int Immunopharmacol  2023,116,109771","journal-title":"Int Immunopharmacol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/hmg\/ddx198","volume":"26","author":"Garc\u00eda-D\u00edaz Barriga G.","year":"2017","unstructured":"Garc\u00eda-D\u00edaz Barriga G.; Giralt A.; Anglada-Huguet M.; 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington\u2019s disease mouse model through specific activation of the PLC\u03b31 pathway. Hum Mol Genet  2017,26(16),3144-3160","journal-title":"Hum Mol Genet"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.nbd.2010.08.017","volume":"41","author":"Hathorn T.","year":"2011","unstructured":"Hathorn T.; Snyder-Keller A.; Messer A.; Nicotinamide improves motor deficits and upregulates PGC-1\u03b1 and BDNF gene expression in a mouse model of Huntington\u2019s disease. Neurobiol Dis  2011,41(1),43-50","journal-title":"Neurobiol Dis"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/35008142","volume":"404","author":"van Dellen A.","year":"2000","unstructured":"van Dellen A.; Blakemore C.; Deacon R.; York D.; Hannan A.J.; Delaying the onset of Huntington\u2019s in mice. Nature  2000,404(6779),721-722","journal-title":"Nature"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.10094","volume":"51","author":"Hockly E.","year":"2002","unstructured":"Hockly E.; Cordery P.M.; Woodman B.; Environmental enrichment slows disease progression in R6\/2 Huntington\u2019s disease mice. Ann Neurol  2002,51(2),235-242","journal-title":"Ann Neurol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.expneurol.2004.01.003","volume":"187","author":"Schilling G.","year":"2004","unstructured":"Schilling G.; Savonenko A.V.; Coonfield M.L.; Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol  2004,187(1),137-149","journal-title":"Exp Neurol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1523\/JNEUROSCI.1658-03.2004","volume":"24","author":"Spires T.L.","year":"2004","unstructured":"Spires T.L.; Grote H.E.; Varshney N.K.; Environmental enrichment rescues protein deficits in a mouse model of Huntington\u2019s disease, indicating a possible disease mechanism. J Neurosci  2004,24(9),2270-2276","journal-title":"J Neurosci"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/01376517-200106000-00005","volume":"33","author":"Sullivan F.R.","year":"2001","unstructured":"Sullivan F.R.; Bird E.D.; Alpay M.; Cha J.H.J.; Remotivation therapy and Huntington\u2019s disease. J Neurosci Nurs  2001,33(3),136-142","journal-title":"J Neurosci Nurs"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/hipo.20658","volume":"20","author":"Zajac M.S.","year":"2010","unstructured":"Zajac M.S.; Pang T.Y.C.; Wong N.; Wheel running and environmental enrichment differentially modify exon\u2010specific BDNF expression in the hippocampus of wild\u2010type and pre\u2010motor symptomatic male and female Huntington\u2019s disease mice. Hippocampus  2010,20(5),621-636","journal-title":"Hippocampus"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.neuroscience.2006.04.013","volume":"141","author":"Pang T.Y.C.","year":"2006","unstructured":"Pang T.Y.C.; Stam N.C.; Nithianantharajah J.; Howard M.L.; Hannan A.J.; Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington\u2019s disease transgenic mice. Neuroscience  2006,141(2),569-584","journal-title":"Neuroscience"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666240530105516","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/230493\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666240530105516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:49:10Z","timestamp":1738234150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/230493\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":172,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x22666240530105516","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}